Published in Pharma Investments, Ventures and Law Weekly, September 18th, 2005
The collaboration, funded in part by an Innovatiesubsidie Samenwerkingsprojecten grant from the Dutch Ministry of Economic Affairs, brings together three Benelux biotech companies and a Dutch university.
As a member of the collaborative effort, Galapagos will contribute its arthritis disease biology and a validated target for drug development, which has been discovered using its small-interfering RNA-based technologies. ZoBio will be responsible for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly